Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. - Wikidata - awgldk - TriplyDB

Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency.

Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency.

http://www.wikidata.org/entity/Q44362847

about

Diabetic kidney disease: a report from an ADA Consensus Conference Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.Management of Hyperglycemia in Diabetic Kidney Disease.Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes.Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.Linagliptin as add-on therapy to insulin for patients with type 2 diabetes The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease Modeling and predicting drug pharmacokinetics in patients with renal impairment.Examining the safety of PPAR agonists - current trends and future prospects.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin.Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling.Non-genomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation.Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation.Blockade of human HERG K⁺ channels by rosiglitazone, an antidiabetic drug.

P2860

Q27012546-DFD4FAD5-7BB2-46F4-B528-600F99B011FA Q31025919-3B243A04-5B36-41C3-8360-B83982451793 Q35953856-0C76571B-B23E-47E0-9A5F-4AF7FF692695 Q36560252-CBA00690-6E70-4727-BF32-CE5E589E5FBB Q36877514-07B7842A-BF45-49E3-9198-4A437B489BD8 Q36883337-0DD1C5EF-802B-4915-84BA-F6AE710075D5 Q37042128-69C4C668-5F33-4FB6-9128-83A47F3F231A Q37281205-A090D772-5C53-4A0F-AD59-4088BA37E590 Q37464712-72DF3117-944F-402B-9C5F-D542416D499C Q37960638-269E6D67-BEBE-4C69-8BDA-CF223FFCB592 Q38058381-900EA8A0-7A1C-4879-8CD6-698E505AC90C Q38086611-58E87A5B-0B1A-4C2B-BB26-0EB103B80AC9 Q38497122-5F167A23-0D1E-4E58-80F1-7F6D480468F9 Q38688345-E4A8AE2B-FA1D-44F0-B753-B26347DA7D7E Q39955398-27662786-F906-45A1-9A30-ED20D7B25723 Q41928597-741A6361-0923-4890-B1BA-9F29A78E28E5 Q48034616-71FAF23D-A2F0-40BC-9FEA-4D766B1F8054 Q54721447-73C8F872-7E96-477B-83DA-AE386A145823

P2860

Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency.

http://www.wikidata.org/entity/Q44362847

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Pharmacokinetics of rosiglitaz ...... egrees of renal insufficiency.

@en

Pharmacokinetics of rosiglitaz ...... egrees of renal insufficiency.

@nl

type

label

Pharmacokinetics of rosiglitaz ...... egrees of renal insufficiency.

@en

Pharmacokinetics of rosiglitaz ...... egrees of renal insufficiency.

@nl

prefLabel

Pharmacokinetics of rosiglitaz ...... egrees of renal insufficiency.

@en

Pharmacokinetics of rosiglitaz ...... egrees of renal insufficiency.

@nl

P1433

Q44362847-FA62A213-87F1-4A38-8EE3-2DB37B57D961

P1476

Q44362847-5C6DDEF9-36EA-4054-B4B3-8E8B5F01B8A1

P2093

Q44362847-09E615F7-7ADC-4F8B-8220-964CCE71C311

Q44362847-51B598C9-2035-4F4B-A57A-F7C21FD7AF5F

Q44362847-DD21F891-F2BA-4420-8D92-3236DDF89977

Q44362847-E30FE364-4F1D-454F-97AB-51B810EDEB3A

Q44362847-F80EA3F3-D79F-4233-8088-C0158B9DA39A

Q44362847-FD492202-FE90-4BC2-A611-511EA3171CEA

P2860

Q44362847-0FC9EDB6-945C-44A1-A99C-3BC5B03AA6EE

Q44362847-232037A0-5A03-4DA8-850C-0B83F4612896

Q44362847-3609F804-3AA6-4081-BB37-243A5811569D

Q44362847-76078ED1-CD94-4ED1-9CE4-B25EA715A17E

Q44362847-7AF499CE-3F1C-4DFC-B373-0DC768204276

Q44362847-96E910E1-C8FD-497A-A8E8-896731B43011

Q44362847-9D0CAB17-E5EA-414E-B19D-F80CFD391D0B

Q44362847-BB1622B4-3E7C-42E5-A32F-FEF26F14074D

Q44362847-E671F07D-30A3-4E9E-B1DF-B6DADB07C349

Q44362847-EABFF5A3-55AF-4D8A-A46D-9A3C5E1E4F9D

P304

Q44362847-BBA5AE90-849E-4300-9FB5-83B99CFBCFEB

P31

Q44362847-0CBD38AC-0A21-4255-A406-D115F694A977

P356

Q44362847-385BD23A-89D2-4431-890F-86A6CD5B34B5

P433

Q44362847-B51C3EA6-F90A-4D20-A402-264DA0D00816

P478

Q44362847-30C7F269-A1D7-4BE5-A1A7-C4E1B847B8D1

P577

Q44362847-70DE6647-C57C-461A-B119-87463ECBA570

P698

Q44362847-A196E828-35C4-46FE-8D6B-92396B8C6A2B

P356

0091270002250602

P1433

The Journal of Clinical Pharmacology

P1476

Pharmacokinetics of rosiglitaz ...... egrees of renal insufficiency.

@en

P2093

Ann K Miller

http://www.w3.org/2001/XMLSchema#string

Kathleen Thompson-Culkin

http://www.w3.org/2001/XMLSchema#string

Marshall Sack

http://www.w3.org/2001/XMLSchema#string

Martha C Chapelsky

http://www.w3.org/2001/XMLSchema#string

Martin I Freed

http://www.w3.org/2001/XMLSchema#string

Robert Blum

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of creatinine clearance from serum creatinine

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Nonlinear pharmacokinetics: clinical Implications.

Factors influencing drug protein binding in patients with end stage renal failure.

Long-term complications of diabetes mellitus.

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.

Focus on insulin resistance in type 2 diabetes: therapeutic implications.

Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study.

P304

252-259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270002250602

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2003-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12638393

http://www.w3.org/2001/XMLSchema#string